HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Free Full Text (PDF) Free Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LENTSCH, A. B. Search for Related Content PubMed PubMed Citation Articles by LENTSCH, A. B.

The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white?

Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA

¹Correspondence: Department of Surgery, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0558, USA. E-mail: alex.lentsch{at}uc.edu

ABSTRACT

Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related death among men in the United States. African American men have a 60% greater incidence of prostate cancer and a twofold higher mortality rate than Caucasian men. The Duffy antigen/receptor for chemokines (DARC) is a receptor expressed on erythrocytes and vascular endothelial cells that binds to and clears angiogenic chemokines. The DARC also functions as the erythrocyte receptor for invasion by malarial parasites. Approximately 70% of African Americans lack erythrocyte expression of the DARC as a genetic mechanism of protection against malaria infection. Given the importance of angiogenic chemokines in the development of tumor vascular networks and the chemokine binding properties of the DARC, the possibility that a lack of DARC expression on erythrocytes may represent an epigenetic factor that predisposes African American men to a greater incidence and mortality of prostate cancer should be considered.—Lentsch, A. B. The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white?

Key Words: angiogenesis • tumor • neovascularization

This article has been cited by other articles:

				C. Vergara, Y. J. Tsai, A. V. Grant, N. Rafaels, L. Gao, T. Hand, M. Stockton, M. Campbell, D. Mercado, M. Faruque, et al. Gene Encoding Duffy Antigen/Receptor for Chemokines Is Associated with Asthma and IgE in Three Populations Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1017 - 1022. [Abstract] [Full Text] [PDF]

				F.-Y. Wu, Z.-L. Ou, L.-Y. Feng, J.-M. Luo, L.-P. Wang, Z.-Z. Shen, and Z.-M. Shao Chemokine Decoy Receptor D6 Plays a Negative Role in Human Breast Cancer Mol. Cancer Res., August 1, 2008; 6(8): 1276 - 1288. [Abstract] [Full Text] [PDF]

				H. Shen and A. B. Lentsch Progressive dysregulation of transcription factors NF-{kappa}B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines Am J Physiol Cell Physiol, April 1, 2004; 286(4): C840 - C847. [Abstract] [Full Text] [PDF]